global direction, page-15

re: 2-4% chicken feed compared to 7.5% MERIAL
Dr. Marcus Remmers, Head of Business Development at Merial, said, "We are very excited about the adenovirus vector as a potential delivery platform. Given the current results to date and significant increases in productivity evidenced from the initial trials, we believe the market potential for these products could be significant, both in terms of providing an alternative to in-feed antibiotics and safely improving profitability for producers."


IMUGENE
Imugene's managing director Dr Warwick Lamb said there were about 46 billion chickens produced each year around the world.

"Practically all chickens in commercial production sheds around the world are fed antibiotics," Dr Lamb said.

"When (the antibiotics) are progressively removed... the producers are going to lose three or four per cent of their production, so they are looking at ways of replacing that."

Imugene is developing a productivity enhancer that can be added to water to make chickens grow bigger, and the product has already undergone eight clinical trials.
The trials showed the product resulted in an average weight increase of 7.5 per cent or 130 grams per chicken.

Dr Lamb said the timing of when the product goes to market was largely under the control of global animal health company Merial Ltd, which has taken an option over Imugene's product as part of an agreement.

"Our predictions are for mid to late 2006 to 2007," Dr Lamb said.

He said he hoped to make about $1 billion a year from the product "at the top end" of his estimates